Login Register Cart 0
Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Back
Research Article

Structure-guided Development of Novel Benzothiophene Derivatives as PLK1-PBD Inhibitors

Author(s): Daowei Huang, Jing Zhang, Xiaocong Yang, Xiangduan Tan, Tingting Chai, Lindeng Ma, Bingyang Zhao, Ying Chen, Jixia Yang* and Yue Zhang*

Volume 21, Issue 11, 2024

Published on: 13 July, 2023

Page: [2163 - 2174] Pages: 12

DOI: 10.2174/1570180820666230602153458

Price: $65

Abstract

Background: Polo-like kinase 1 (PLK1), a validated target for tumor therapy, plays a key role in mitosis and is over-expressed in many tumors. In addition to its N-terminal kinase domain, PLk1 also harbors a C-terminal polo-box domain (PBD).

Objective: A candidate based on PLK1-PBD was developed as a promising compound for future development.

Methods: Seventeen small molecule PLK1-PBD inhibitors were designed, synthesized and evaluated for PLK1-PBD inhibitory activities by fluorescence polarization (FP) assay. The compounds with better inhibitory activities were further assessed for their anti-proliferative activities using a CCK-8 method.

Results: The inhibitory rates of compounds 7a, 7d, 14a, 14d, 14e and 14f exceeded 98%. The IC50 values of compounds 7d, 14d, 14e, and 14f were 0.73 μM, 0.67 μM, 0.89 μM and 0.26 μM, proving better than MCC1019. Compound 14f showed the best inhibitory activity (IC50: 0.26 μM) and antiproliferative activities against three cancer cell lines (HeLa, HepG2 and MG63). Especially, compound 14f also exhibited acceptable safety profiles in the human ether-a-go-go related gene (hERG) and normal cell tests. The results of docking and prediction studies indicated that compound 14f had a high binding affinity to the target, with good drug-like absorption, distribution, metabolism, elimination, and toxicity (ADMET) properties.

Conclusion: Compound 14f can be a promising compound for future development.

« Previous Next »
[1]
Strebhardt, K. Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy. Nat. Rev. Drug Discov., 2010, 9(8), 643-660.
[http://dx.doi.org/10.1038/nrd3184] [PMID: 20671765]
[2]
Raab, C.A.; Raab, M.; Becker, S.; Strebhardt, K. Non-mitotic functions of polo-like kinases in cancer cells. Biochim. Biophys. Acta Rev. Cancer, 2021, 1875(1), 188467.
[http://dx.doi.org/10.1016/j.bbcan.2020.188467] [PMID: 33171265]
[3]
Zhang, Z.; Xing, X.; Guan, P.; Song, S.; You, G.; Xia, C.; Liu, T. Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies. Eur. J. Med. Chem., 2021, 217, 113314.
[http://dx.doi.org/10.1016/j.ejmech.2021.113314] [PMID: 33765606]
[4]
Wang, L.; Guo, Q.; Fisher, L.A.; Liu, D.; Peng, A. Regulation of polo-like kinase 1 by DNA damage and PP2A/B55α. Cell Cycle, 2015, 14(1), 157-166.
[http://dx.doi.org/10.4161/15384101.2014.986392] [PMID: 25483054]
[5]
Gheghiani, L.; Loew, D.; Lombard, B.; Mansfeld, J.; Gavet, O. PLK1 activation in late G2 sets up commitment to mitosis. Cell Rep., 2017, 19(10), 2060-2073.
[http://dx.doi.org/10.1016/j.celrep.2017.05.031] [PMID: 28591578]
[6]
Zhang, Z.; Cheng, L.; Zhang, Q.; Kong, Y.; He, D.; Li, K.; Rea, M.; Wang, J.; Wang, R.; Liu, J.; Li, Z.; Yuan, C.; Liu, E.; Fondufe-Mittendorf, Y.N.; Li, L.; Han, T.; Wang, C.; Liu, X. Co‐targeting Plk1 and DNMT3a in advanced prostate cancer. Adv. Sci., 2021, 8(13), 2101458.
[http://dx.doi.org/10.1002/advs.202101458] [PMID: 34051063]
[7]
Nieto-Jimenez, C.; Galan-Moya, E.M.; Corrales-Sanchez, V.; Noblejas-Lopez, M.M.; Burgos, M.; Domingo, B.; Montero, J.C.; Gomez-Juarez, M.; Picazo-Martinez, M.G.; Esparis-Ogando, A.; Pandiella, A.; Ocaña, A. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer. Cancer Lett., 2020, 491, 50-59.
[http://dx.doi.org/10.1016/j.canlet.2020.06.020] [PMID: 32735909]
[8]
Fu, Z.; Su, M.; Liu, X.; Chen, Y. [Mining polo-box domain of polo-like kinase 1 as a new therapeutic target for cancer]. Chin. J. Biotechnol., 2020, 36(11), 2298-2312.
[PMID: 33244925]
[9]
Shakeel, I.; Basheer, N.; Hasan, G.M.; Afzal, M.; Hassan, M.I. Polo-like Kinase 1 as an emerging drug target: Structure, function and therapeutic implications. J. Drug Target., 2021, 29(2), 168-184.
[http://dx.doi.org/10.1080/1061186X.2020.1818760] [PMID: 32886539]
[10]
de Cárcer, G.; Manning, G.; Malumbres, M. From Plk1 to Plk5: Functional evolution of polo-like kinases. Cell Cycle, 2011, 10(14), 2255-2262.
[http://dx.doi.org/10.4161/cc.10.14.16494] [PMID: 21654194]
[11]
Liu, F.; Park, J.E.; Qian, W.J.; Lim, D.; Gräber, M.; Berg, T.; Yaffe, M.B.; Lee, K.S.; Burke, T.R., Jr Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Nat. Chem. Biol., 2011, 7(9), 595-601.
[http://dx.doi.org/10.1038/nchembio.614] [PMID: 21765407]
[12]
Ahn, M.; Han, Y.H.; Park, J.E.; Kim, S.; Lee, W.C.; Lee, S.J.; Gunasekaran, P.; Cheong, C.; Shin, S.Y., Sr; Kim, H.Y.; Ryu, E.K.; Murugan, R.N.; Kim, N.H.; Bang, J.K. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1. J. Med. Chem., 2015, 58(1), 294-304.
[http://dx.doi.org/10.1021/jm501147g] [PMID: 25347203]
[13]
Gali-Muhtasib, H.; Roessner, A.; Schneider-Stock, R. Thymoquinone: A promising anti-cancer drug from natural sources. Int. J. Biochem. Cell Biol., 2006, 38(8), 1249-1253.
[http://dx.doi.org/10.1016/j.biocel.2005.10.009] [PMID: 16314136]
[14]
Reindl, W.; Yuan, J.; Krämer, A.; Strebhardt, K.; Berg, T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem. Biol., 2008, 15(5), 459-466.
[http://dx.doi.org/10.1016/j.chembiol.2008.03.013] [PMID: 18482698]
[15]
Yuan, J.; Sanhaji, M.; Krämer, A.; Reindl, W.; Hofmann, M.; Kreis, N.N.; Zimmer, B.; Berg, T.; Strebhardt, K. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am. J. Pathol., 2011, 179(4), 2091-2099.
[http://dx.doi.org/10.1016/j.ajpath.2011.06.031] [PMID: 21839059]
[16]
Scharow, A.; Raab, M.; Saxena, K.; Sreeramulu, S.; Kudlinzki, D.; Gande, S.; Dötsch, C.; Kurunci-Csacsko, E.; Klaeger, S.; Kuster, B.; Schwalbe, H.; Strebhardt, K.; Berg, T. Optimized Plk1 PBD inhibitors based on poloxin induce mitotic arrest and apoptosis in tumor cells. ACS Chem. Biol., 2015, 10(11), 2570-2579.
[http://dx.doi.org/10.1021/acschembio.5b00565] [PMID: 26279064]
[17]
Abdelfatah, S.; Berg, A.; Huang, Q.; Yang, L.J.; Hamdoun, S.; Klinger, A.; Greten, H.J.; Fleischer, E.; Berg, T.; Wong, V.K.W.; Efferth, T. MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate. Acta Pharm. Sin. B, 2019, 9(5), 1021-1034.
[http://dx.doi.org/10.1016/j.apsb.2019.02.001] [PMID: 31649851]
[18]
Wang, L.; Ren, Z.L.; Ding, M.W. Synthesis of 2,3-Dihydro-1 H -2-benzazepin-1-ones and 3 H -2-benzoxepin-1-ones by isocyanide-based multicomponent reaction/wittig sequence starting from phosphonium salt precursors. J. Org. Chem., 2015, 80(1), 641-646.
[http://dx.doi.org/10.1021/jo502275f] [PMID: 25469708]
[19]
Zhang, Z.; Zhang, B.S.; Li, K.L.; An, Y.; Liu, C.; Gou, X.Y.; Liang, Y.M. Palladium-catalyzed amination/dearomatization reaction of indoles and benzofurans. J. Org. Chem., 2020, 85(12), 7817-7839.
[http://dx.doi.org/10.1021/acs.joc.0c00475] [PMID: 32441518]
[20]
Hou, S.; Yang, X.; Tong, Y.; Yang, Y.; Chen, Q.; Wan, B.; Wei, R.; Wang, Y.; Zhang, Y.; Kong, B.; Huang, J.; Chen, Y.; Lu, T.; Hu, Q.; Du, D. Structure-based discovery of 1H-indole-2-carboxamide derivatives as potent ASK1 inhibitors for potential treatment of ulcerative colitis. Eur. J. Med. Chem., 2021, 211, 113114.
[http://dx.doi.org/10.1016/j.ejmech.2020.113114] [PMID: 33360793]
[21]
Abdel-Aziz, H.A.; Mekawey, A.A.I.; Dawood, K.M. Convenient synthesis and antimicrobial evaluation of some novel 2-substituted-3-methylbenzofuran derivatives. Eur. J. Med. Chem., 2009, 44(9), 3637-3644.
[http://dx.doi.org/10.1016/j.ejmech.2009.02.020] [PMID: 19321238]
[22]
Soni, J.N.; Soman, S.S. Synthesis and antimicrobial evaluation of amide derivatives of benzodifuran-2-carboxylic acid. Eur. J. Med. Chem., 2014, 75, 77-81.
[http://dx.doi.org/10.1016/j.ejmech.2014.01.026] [PMID: 24530493]
[23]
Kim, J.; Jung, Y.K.; Kim, C.; Shin, J.S.; Scheers, E.; Lee, J.Y.; Han, S.B.; Lee, C.K.; Neyts, J.; Ha, J.D.; Jung, Y.S. A novel series of highly potent small molecule inhibitors of rhinovirus replication. J. Med. Chem., 2017, 60(13), 5472-5492.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00175] [PMID: 28581749]
[24]
Zhang, F.; Li, L.; Zhang, J.; Gong, H. Metal- and solvent-free synthesis of amides using substitute formamides as an amino source under mild conditions. Sci. Rep., 2019, 9(1), 2787.
[http://dx.doi.org/10.1038/s41598-019-39240-z] [PMID: 30808919]
[25]
Zarei, O.; Azimian, F.; Hamzeh-Mivehroud, M.; Shahbazi, M.J.; Hemmati, S.; Dastmalchi, S. Design, synthesis, and biological evaluation of novel benzo[b]thiophene-diaryl urea derivatives as potential anticancer agents. Med. Chem. Res., 2020, 29(8), 1438-1448.
[http://dx.doi.org/10.1007/s00044-020-02559-8]
[26]
Chen, Y.; Zhang, J.; Li, D.; Jiang, J.; Wang, Y.; Si, S. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. Oncotarget, 2017, 8(1), 1234-1246.
[http://dx.doi.org/10.18632/oncotarget.13603] [PMID: 27902479]
[27]
Wu, T.; Qin, Q.; Liu, N.; Zhang, C.; Lv, R.; Yin, W.; Sun, Y.; Sun, Y.; Wang, R.; Zhao, D.; Cheng, M. Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold. Eur. J. Med. Chem., 2022, 230, 114096.
[http://dx.doi.org/10.1016/j.ejmech.2021.114096] [PMID: 35007864]
[28]
Huang, D.; Huang, L.; Zhang, Q.; Li, J. Synthesis and biological evaluation of novel 6,11-dihydro-5 H-benzo[e]pyrimido-[5,4- b][1,4]diazepine derivatives as potential c-Met inhibitors. Eur. J. Med. Chem., 2017, 140, 212-228.
[http://dx.doi.org/10.1016/j.ejmech.2017.08.060] [PMID: 28938137]
[29]
Walters, W.P. Going further than Lipinski’s rule in drug design. Expert Opin. Drug Discov., 2012, 7(2), 99-107.
[http://dx.doi.org/10.1517/17460441.2012.648612] [PMID: 22468912]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy